Drugs /

testosterone cypionate

Back to Drugs List

Overview

NCI Definition [1]:
An eight-carbon ester form of Testosterone. The number of ester carbon atoms correlate with the half-life of the prodrug. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels. In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males. (NCI04)

Clinical Trials

View Clinical Trials for testosterone cypionate

Testosterone cypionate has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating testosterone cypionate, 1 is phase 1 (0 open) and 2 are phase 2 (2 open).

Prostate adenocarcinoma is the most common disease being investigated in testosterone cypionate clinical trials [2].

Drug Details

Synonyms [2]:
testosterone cypionate preparation, depo-testosterone, 17beta-cyclopentanepropionate, testosterone cypionate, testosterone 17 beta-cypionate [chemical/ingredient], depo-testosterone cypionate, depotest, 17beta-cyclopentanepropionate, depandro, pertestis, testosterone 17 beta-cyclopentylpropionate, testosterone cypionate (substance), virilon, star brand of methyltestosterone, testosterone cypionate, testosterone 17 beta-cypionate, androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17-beta)-, depo-testosterone, virilon im, 58-20-8, testosterone cypionate preparation (product), depovirin, testosterone 17 beta-cyclopentanepropionate, testosterone cypionate
Drug Target(s) [2]:
AR
NCIT ID [1]:
C1246
SNOMED ID [1]:
C-A0502

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.